The patent win removes a major overhang on MINOCIN® sales. Monitor for any potential appeal by Nexus (unlikely given Federal Circuit affirmation) and watch next quarterly revenue for acceleration. The ruling strengthens the bull case for CRMD as a single-product commercial biotech with extended patent protection.
CRMD drugs
CRMD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 8 $8.54entry
- T+1 · 5mo ago +1.29%α +1.58% · $8.65
- T+5 · 5mo ago +0.59%α −1.53% · $8.59
- T+20 · 4mo ago +2.93%α +1.30% · $8.79
- T+60 · 3mo ago −1.87%α −4.93% · $8.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CorMedix announced that the Federal Circuit affirmed a district court ruling upholding the validity and infringement of its MINOCIN® patents against Nexus Pharmaceuticals, with a permanent injunction barring Nexus from marketing its generic minocycline product before patent expiration. This removes a key competitive threat to MINOCIN® revenue, protecting CorMedix's primary commercial asset. The ruling is a material positive for the company's intellectual property moat and near-term revenue outlook.
Key Facts
- Federal Circuit affirmed district court judgment that MINOCIN® patents are valid and infringed by Nexus Pharmaceuticals.
- Permanent injunction bars Nexus from marketing its generic minocycline product prior to patent expiration.
- Patents-at-issue are FDA Orange Book listed, protecting MINOCIN® for Injection.
- MINOCIN® is a tetracycline-derived antibiotic used in hospital and acute care settings for serious and drug-resistant infections.
Financial Impact
Protects MINOCIN® revenue stream from generic competition until patent expiration; no specific revenue or market size disclosed in filing.
Risk Factors
- Nexus could petition for Supreme Court certiorari, though likelihood is low.
- MINOCIN® remains a single-product revenue stream; any commercial setbacks or supply issues would still be impactful.
- Patent expiration timeline not disclosed; eventual generic entry remains a long-term risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308104 |
Track record
21 reports on CRMD
8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers